Generali Asset Management SPA SGR Lowers Stock Position in Boston Scientific Corporation $BSX

Generali Asset Management SPA SGR trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 11.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,305 shares of the medical equipment provider’s stock after selling 11,273 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Boston Scientific were worth $8,948,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Ritholtz Wealth Management increased its stake in Boston Scientific by 3.5% in the second quarter. Ritholtz Wealth Management now owns 36,284 shares of the medical equipment provider’s stock valued at $3,897,000 after purchasing an additional 1,225 shares during the period. Harbour Investments Inc. grew its holdings in shares of Boston Scientific by 17.3% during the second quarter. Harbour Investments Inc. now owns 6,308 shares of the medical equipment provider’s stock worth $678,000 after buying an additional 929 shares during the last quarter. Cypress Wealth Services LLC increased its position in Boston Scientific by 8.4% in the 2nd quarter. Cypress Wealth Services LLC now owns 2,754 shares of the medical equipment provider’s stock valued at $296,000 after acquiring an additional 214 shares during the period. J.Safra Asset Management Corp raised its stake in Boston Scientific by 2.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 7,749 shares of the medical equipment provider’s stock valued at $826,000 after acquiring an additional 197 shares during the last quarter. Finally, Bayforest Capital Ltd lifted its position in Boston Scientific by 511.6% during the 2nd quarter. Bayforest Capital Ltd now owns 2,263 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 1,893 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 1.4%

Shares of Boston Scientific stock opened at $96.26 on Wednesday. The company has a 50-day moving average of $101.58 and a two-hundred day moving average of $101.80. The stock has a market cap of $142.63 billion, a PE ratio of 57.30, a price-to-earnings-growth ratio of 2.29 and a beta of 0.61. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on BSX shares. Raymond James Financial upped their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Canaccord Genuity Group raised their target price on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Robert W. Baird raised their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $120.71.

Insider Buying and Selling at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $17,972,457 in the last quarter. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.